Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Cancer Discovery|January 30, 2023
LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung AdenocarcinomaBenjamin D Stein, John R Ferrarone, Eric E Gardner, et al.
The Journal of Clinical Investigation|February 23, 2012
Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiencyLaure Gineau, Céline Cognet, Nihan Kara, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 8, 2018
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsPang-Dian Fan, Giuseppe Narzisi, Anitha D Jayaprakash, et al.
Cancer Cell|May 8, 2007
Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeuticsJennifer A MacDiarmid, Nancy B Mugridge, Jocelyn C Weiss, et al.
Science (New York, N.Y.)|June 28, 2003
Medicine. The need for a global HIV vaccine enterpriseRichard D Klausner, Anthony S Fauci, Lawrence Corey, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2005
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesTodd A Carter, Lisa M Wodicka, Neil P Shah, et al.
Cell Reports|February 9, 2022
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cellsFraser D Johnson, John Ferrarone, Alvin Liu, et al.
Plos One|April 7, 2016
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a ModelJennifer A MacDiarmid, Veronika Langova, Dale Bailey, et al.
Cold Spring Harbor Perspectives in Medicine|November 5, 2014
Rhabdomyosarcoma: current challenges and their implications for developing therapiesSimone Hettmer, Zhizhong Li, Andrew N Billin, et al.
Molecular Oncology|December 15, 2025
Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities: Proceedings from a conference organised by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, held in Vatican City, May 22-23, 2025Ulrik Ringborg, Joachim von Braun, Julio Celis, et al.
Pageof 13